Showing 121-132 of 446 Results
Article
Biopharma IPOs: Trends in Executive Compensation Planning and Design
A review of exec pay trends and data from newly public biopharmas.
Client Alert
FTC Issues Final Rule Generally Banning All Noncompetes in the United States
Details on the Final Rule, which has potentially broad and dramatic implications for almost all US employers, and how you can prepare.
Webcast
Compensation Peer Groups: Everything You Need to Know Right Now
Practical tips for structuring compensation peer groups and using the data to inform executive compensation decisions.
Advisor Blog
A Standard Board Assessment Process is No Longer Enough
How to get started framing an evaluation that can help the board improve its collaboration and effectiveness.
Case Study
Case Study: CEO Evaluation Facilitates Dialog and Development
A global, public company board and its CEO look for a clear and actionable executive assessment process.
Research Report
AI’s Impact on Organizational Structure and Investments
The results from a recent Pearl Meyer Quick Poll on AI point to a few emerging trends and uncover some surprising data points.
Article
Biopharma Fundraising and the Related Compensation Considerations
After a new funding round, there are three specific compensation questions to address.
Advisor Blog
Analyzing "At Appointment" Equity Awards for New Directors
As some companies are considering this strategy to attract top-tier board talent, we offer prevalence data and the pros and cons.
Advisor Blog
IRS to Ramp Up Private Jet Usage Audits
Aircraft use by executives and directors for business and personal reasons involves complex tax, disclosure, and governance implications.
Article
To Maximize ROI, Equity May Need to Go Deeper
Is it time to examine long-standing views on executive equity allocation strategy and all-employee ownership opportunities?
Webcast
New Year, New Data: Digging in to the Latest Director Compensation Study
Evaluate your board’s compensation levels and practices against the market.
Article
Key Considerations for Biopharma Equity Plan Amendments
Biopharma companies with share constraints can adopt several best practice provisions to maximize the chance of success.